Imfinzi(durvalumab)

[Function and indications] On May 1, 2017, the U.S. FDA approved Imfinzi for the treatment of locally advanced or metastatic urothelial cell carcinoma

[Model and specifications] Injection: 500 mg/10mL; 120 mg/2.4mL

[Usage and dosage] 10 mg/kg is given as an intravenous infusion over 60 minutes every 2 weeks

[Adverse reactions] The most common adverse events (reported in ≥15% of patients) are fatigue, musculoskeletal pain, constipation, loss of appetite, nausea, peripheral edema, and urinary tract infection.

[Manufacturer] Imfinzi is developed by AstraZeneca Pharmaceuticals

Note: If the drug has a new packaging, the new packaging shall prevail. The above information comes from the Internet or is translated by student volunteers from higher medical colleges (if there are any errors or omissions, please help correct them). It is only for internal discussion among medical staff and is not used as any basis for medication. For specific medication instructions, please consult the attending physician.